Evidence map›Paper›PMID 34949922›Full record

ReviewInternational journal of nanomedicine2021

Chitosan Nanoparticles for Antiviral Drug Delivery: A Novel Route for COVID-19 Treatment.

Abdel-Majed Safer, Stefano Leporatti

Open access · goldAbstract readReview
In one paragraph

Review in International journal of nanomedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Abdel-Majed SaferDepartment of Biological Sciences, Faculty of Science, Kuwait University, Kuwait City, Kuwait.ORCID 0000-0002-1037-2460
Stefano LeporattiCNR Nanotec, Istituto di Nanotecnologia, Lecce, 73100, Italy.ORCID 0000-0001-5912-7565
Istituto Nanoscienze · ITKuwait University · KW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chitosan has been investigated in several biological fields, including drug and gene delivery, tissue engineering antiviral and immunological adjuvant methods. It's a cationic copolymer of N-acetyl glucosamine and D-glucosamine with different molecular chain lengths, compositions, and sequences than N-acetyl glucosamine and D-glucosamine. It is biocompatible and cyto-compatible, as well as recyclable and bioresorbable. As effective drug delivery methods, chitosan nanoparticles are shaped into several pathways. The purpose of this article is to provide an overview of its antiviral application as a nanocarrier for antiviral medications, highlighting the benefits, limitations, and downsides. In this review, we will report the most recent COVID-19 vaccination advances. It will also be discussed what the future holds for chitosan nanoparticles in the treatment of coronaviruses.

Indexed as

ChitosanCOVID-19 Drug TreatmentNanoparticlesAntiviral AgentsCOVID-19 VaccinesDrug CarriersDrug Delivery SystemsHumansSARS-CoV-2Antiviral AgentsChitosanCOVID-19 VaccinesDrug CarriersantiviralschitosanCOVID-19drug deliverynanoparticles

Identifiers

PMID34949922
PMCPMC8689047
OpenAlexW4200165921

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.